Day: March 15, 2023

SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 2022. “In 2022, we achieved three key goals that set us up for a transformative 2023: First, we achieved positive 24-week data from our Phase 2 BEHOLD study in UBX1325 in patients with diabetic macular edema, a ground-breaking clinical proof-of-concept for our novel senolytic small molecule and for the senescence biology and anti-aging field. Second, we completed an important and upsized financing to accelerate value generation in our clinical development of UBX1325,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “And third,...

Near-term data readouts from internal and collaborative programs expected to support advancement of the LNC platform for delivery of nucleic acids FDA feedback from MAT2203 Type B meeting expected to impact partnership discussions and facilitate potential non-dilutive BARDA and/or NIH funding Conference call and webcast begin at 4:30 p.m. Eastern time today BEDMINSTER, N.J., March 15, 2023 (GLOBE NEWSWIRE) — Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports 2022 financial results and provides a business update. “We are developing our LNC delivery platform with the goal of providing safe, extrahepatic delivery of nucleic acids and small molecules,” said Jerome D. Jabbour, Chief...

Announced Phase 1 monotherapy dose escalation data for investigational pan-RAF inhibitor exarafenib (KIN-2787) was selected for an oral presentation at the American Association for Cancer Research 2023 Annual MeetingAnnounced the company has initiated enrollment of patients into the monotherapy expansion cohorts evaluating exarafenibAnnounced the U.S. Food and Drug Administration granted Fast Track designation for KIN-3248, our investigational pan-FGFR inhibitorCash, cash equivalents and investments of $266.3 million as of December 31, 2022SAN FRANCISCO and SAN DIEGO, March 15, 2023 (GLOBE NEWSWIRE) —  Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced financial results for the year ended December 31, 2022, and recent corporate updates. “2023 is shaping up...

First patient dosed in expansion portion of KB-0742 Phase 1/2 study, with initial efficacy results expected in 2H 2023 Recommended Phase 2 dose and initial data from Phase 1b/2 study of lanraplenib in combination with gilteritinib in FLT3-mutated AML on track to report in Q4 2023 or Q1 2024 Discovery collaboration with Genentech underway $247.9 million in cash, cash equivalents and investments as of December 31, 2022, providing expected cash runway into the second half of 2025 SAN MATEO, Calif. and CAMBRIDGE, Mass., March 15, 2023 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and fourth-quarter and full-year 2022 financial results. “We have had an exciting start to 2023, with both the announcement of our discovery...

PENNSAUKEN, N.J., March 15, 2023 (GLOBE NEWSWIRE) — RCM Technologies, Inc. (NasdaqGM: RCMT), a premier provider of business and technology solutions designed to enhance and maximize the operational performance of its customers through the adaptation and deployment of advanced engineering, specialty health care, and information technology services, today announced financial results for the thirteen and fifty-two weeks ended December 31, 2022. RCM Technologies reported revenue of $70.2 million for the thirteen weeks ended December 31, 2022 (the current period), an increase of 8.2% compared to $64.9 million for the thirteen weeks ended January 1, 2022 (the comparable prior-year period). Gross profit was $20.5 million for the current period, a 15.0% increase compared to $17.8 million for the comparable prior-year period.  The Company...

Delivered 15.7% Net Sales Growth for Fiscal Year 2022 Generated Net Income of $19.0 million and Adjusted EBITDA of $39.0 million for Fiscal Year 2022 Generated Q4 GAAP Diluted EPS of $0.05 and Q4 Adjusted Diluted EPS of $0.08 Introduces Fiscal 2023 Outlook SAN FRANCISCO, March 15, 2023 (GLOBE NEWSWIRE) — Brilliant Earth Group, Inc. (“Brilliant Earth” or the “Company”) (Nasdaq: BRLT), an innovative, digital-first jewelry company and global leader in ethically sourced fine jewelry, today announced financial results for the three and twelve months ended December 31, 2022. Fourth Quarter and Fiscal Year 2022 Highlights (quarterly and annual periods ended December 31, 2022):Delivered net sales of $119.6 million and $439.9 million for the fourth quarter and fiscal year, respectively, achieving a record level of orders for the year...

LEHI, Utah, March 15, 2023 (GLOBE NEWSWIRE) — Nature’s Sunshine Products, Inc. (Nasdaq: NATR) (“Nature’s Sunshine” and/or the “Company”), a leading natural health and wellness company of premium-quality herbal and nutritional products, reported financial results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 Financial Highlights vs. Same Year-Ago QuarterNet sales were $102.7 million compared to $117.9 million (down 6.4% in constant currency). GAAP net income was $2.1 million, or $0.10 per diluted share, compared to $13.8 million, or $0.67 per diluted share. Adjusted EBITDA was $8.0 million compared to $11.6 million.Full Year 2022 Financial Highlights vs. 2021Net sales were $421.9 million compared to $444.1 million (up 0.2% in constant currency). GAAP net income was $0.6 million, or $(0.02)...

Record fourth quarter revenue of $29.6 million, with 20% year-over-year growth Record full year revenue of $94.9 million with 36% year-over-year growthLAKE FOREST, Calif., March 15, 2023 (GLOBE NEWSWIRE) — ToughBuilt Industries, Inc. (“ToughBuilt”) (NASDAQ: TBLT; TBLTW), today reported financial results for the fourth quarter and full year ended December 31, 2022. Twelve Months Ended December 31, 2022 Financial Highlights:Revenues for the twelve months ended December 31, 2022, were approximately $94.9 million, an increase of 36% compared to 2021. The increase in revenue was primarily the result of wide acceptance of ToughBuilt products, and a combination of onboarding new retail customers, introduction of new SKUs and continued demand for our existing products. Gross profit increased to approximately $21.8 million...

Provided updates on clinical pipeline, including 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for cystic fibrosis lung disease, and 4D-310 for Fabry disease cardiomyopathyDemonstrated robust clinical gene delivery, tolerability and initial biological activity with first three customized and evolved vectors generated from Therapeutic Vector Evolution platformExpanded preclinical pipeline with large market geographic atrophy (GA) and alpha-1 antitrypsin deficiency lung disease (AATLD) programsOn track for multiple clinical data updates on lead clinical-stage product candidates during 2023Cash, cash equivalents and marketable securities sufficient to fund operations into the first half of 2025EMERYVILLE, Calif., March 15, 2023 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq:...

DENVER, March 15, 2023 (GLOBE NEWSWIRE) — EverCommerce Inc. (“EverCommerce” or the “Company”) (NASDAQ: EVCM), a leading service commerce platform, today announced financial results for the quarter and year ended December 31, 2022. Fourth Quarter 2022 Financial HighlightsRevenue of $161.8 million, an increase of 19.3% compared to $135.6 million for the quarter ended December 31, 2021. YoY Pro forma revenue growth rate of approximately 14.2% for the quarter ended December 31, 2022. Net loss was $17.8 million, or ($0.09) per basic and diluted share, for the quarter ended December 31, 2022, compared to net loss of $4.7 million, or ($0.02) per basic and diluted share, for the quarter ended December 31, 2021. Adjusted EBITDA was $35.2 million for the quarter ended December 31, 2022, compared to $29.3 million...